ABOUT

We are pioneering a new class of medicine we call endobody vaccines that are fully synthetic and train the body to safely and efficiently treat and prevent neurological disease.

We are not afraid to be brave and tackle the seemingly impossible. We are committed to transforming the lives of all patients and families affected by Alzheimer’s, Parkinson’s, CTE and other neurological diseases.

We envision a world where neurodegenerative diseases are prophylactically eradicated.

MORE ABOUT US

By The Numbers

80 years ago, it was polio. Today, our epidemic is Alzheimer’s.

50%

CHANCE YOU WILL HAVE ALZHEIMER’S
IF OVER 85 YEARS OLD

100%

FATAL

$1 TRILLION

ANNUAL COST TO THE WORLD

Just as science brought us a vaccine against polio and virtually eradicated the disease worldwide, we are working to develop vaccines to treat and ultimately prevent Alzheimer’s and other neurological diseases.

OUR SCIENCE

We aren’t your average vaccine company.

We have built a robust translational platform to rapidly design and develop targeted immunotherapeutics based on the industry’s leading endobody vaccine technology. After two decades of research and over 3 billion doses commercialized on other indications, we are now developing the world’s most advanced active vaccine against Alzheimer’s.

HOW OUR VACCINES ARE DIFFERENT

NEWS

ViewPoints: Hitting an old target with an older modality- but new progress in AD?

June 17, 2018 -

United Neuroscience is hoping to succeed where others have failed- in neurological diseases in general and with a vaccine approach in particular

Read More

Scrip Asks… What Is The Future Of Biotech?

June 14, 2018 -

United Neuroscience shares their vision of future changes to the rapidly evolving world of biotechnology, predicting what the next five years will bring

Read More

JOIN US

Does achieving the seemingly impossible inspire you? Would you describe yourself as passionate and ambitious? We are constantly looking for dedicated people who enjoy developing breakthrough programs to join our team.

EXPLORE OUR OPPORTUNITIES